Literature DB >> 22940477

Parkinson's disease in patients and obligate carriers of Gaucher disease.

Joanna G Becker1, Gregory M Pastores, Alessandro Di Rocco, Marissa Ferraris, Jerome J Graber, Swati Sathe.   

Abstract

BACKGROUND: Gaucher disease is an autosomal recessive disorder caused by glucocerebrosidase gene mutations. Accumulating evidence from several Parkinson's disease cohorts of varying ethnicities suggests that glucocerebrosidase mutations even in the heterozygous state (carriers) may be a susceptibility factor for Parkinson's. Very few studies have analyzed the frequency of Parkinson's in carriers and individuals with Gaucher disease.
OBJECTIVE: To determine frequency of Parkinson's in patients with Gaucher disease and obligate carriers of glucocerebrosidase mutations and compare it with a control group.
METHODS: A questionnaire was completed by 100 Ashkenazi Jewish Gaucher patients followed at our center and 109 ethnicity-matched controls with no personal or family history of Gaucher disease.
RESULTS: Frequency of Parkinson's was higher in Gaucher patients (8/100) than in controls (0/109; P = 0.0024). Frequency of Parkinson's in obligate carriers (11/200) was higher than controls (6/218), but the difference was not statistically significant (P = 0.215). Average age of onset of Parkinson's was earlier in Gaucher patients (57.2) than the general population and in obligate carriers (60) when compared with controls (76.8; P = 0.01). The L444P genotype was more frequent in Gaucher patients who reported a parent with Parkinson's (36.40%) than those who did not (4.50%).
CONCLUSION: Our study suggests that the risk for developing Parkinson's may be higher in affected versus carriers of glucocerebrosidase mutations and suggests that L444P may pose a higher risk of developing Parkinson's than other mutations. It also confirms previous findings that the age of onset of Parkinson's associated with glucocerebrosidase mutations is earlier than in the general population.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22940477     DOI: 10.1016/j.parkreldis.2012.06.023

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

1.  Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy.

Authors:  Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz
Journal:  J Inherit Metab Dis       Date:  2019-12-17       Impact factor: 4.982

2.  Disclosure of research results in genetic studies of Parkinson's disease caused by LRRK2 mutations.

Authors:  Claustre Pont-Sunyer; Susan Bressman; Deborah Raymond; Amanda Glickman; Eduardo Tolosa; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2015-05-07       Impact factor: 10.338

Review 3.  Glucocerebrosidase is shaking up the synucleinopathies.

Authors:  Marina Siebert; Ellen Sidransky; Wendy Westbroek
Journal:  Brain       Date:  2014-02-14       Impact factor: 13.501

4.  Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.

Authors:  Edward Rockenstein; Jennifer Clarke; Catherine Viel; Nicholas Panarello; Christopher M Treleaven; Changyoun Kim; Brian Spencer; Anthony Adame; Hyejung Park; James C Dodge; Seng H Cheng; Lamya S Shihabuddin; E Masliah; S Pablo Sardi
Journal:  Hum Mol Genet       Date:  2016-04-28       Impact factor: 6.150

5.  Expanded genetic screening panel for the Ashkenazi Jewish population.

Authors:  Brett Baskovich; Susan Hiraki; Kinnari Upadhyay; Philip Meyer; Shai Carmi; Nir Barzilai; Ariel Darvasi; Laurie Ozelius; Inga Peter; Judy H Cho; Gil Atzmon; Lorraine Clark; Jin Yu; Todd Lencz; Itsik Pe'er; Harry Ostrer; Carole Oddoux
Journal:  Genet Med       Date:  2015-09-03       Impact factor: 8.822

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.